The FDA’s Marty Makary and Vinay Prasad have laid out a path for CRISPR treatments on demand. An expert weighs in on what it ...
Promising results from a small clinical trial highlight a growing interest in designing gene-editing treatments for common ...
CRISPR Therapeutics AG is rated a Buy with $1.9B cash, prudent management, and undervalued shares. Learn more about CRSP ...
ZME Science on MSN
Inside the Human Gene Editing Boom Driven by CRISPR Reshaping Everything From Medicine to Food
CRISPR-based technology is advancing rapidly, driving international competition. Its promise to transform medicine is colliding with political and social realities, even as applications expand.
Ben Lamm, founder of Colossal Biosciences, aims to revive extinct species like the woolly mammoth using advanced genetic ...
Intellia faces FDA clinical holds on key ATTR studies as it readies crucial HAE data in 2026, making lonvo-z pivotal for its near-term outlook.
The immune system faces a delicate balancing act: it must be aggressive enough to fight infections and cancer, yet restrained ...
AZoLifeSciences on MSN
FOXP3 Gene Regulation Holds Key to Immune Therapies
The immune system faces a delicate balancing act: it must be aggressive enough to fight infections and cancer, yet restrained ...
10mon MSNOpinion
Ethics should lead, not play catch-up, expert emphasizes as Japan panel OKs making human embryos from stem cells
A leading bioethicist at Hiroshima University is calling for an anticipatory, rather than reactive, approach to ethics after ...
The immune system faces a delicate balancing act: it must be aggressive enough to fight infections and cancer, yet restrained enough to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback